AU2017206006B2 - Modulation of afucosylated species in a monoclonal antibody composition - Google Patents

Modulation of afucosylated species in a monoclonal antibody composition Download PDF

Info

Publication number
AU2017206006B2
AU2017206006B2 AU2017206006A AU2017206006A AU2017206006B2 AU 2017206006 B2 AU2017206006 B2 AU 2017206006B2 AU 2017206006 A AU2017206006 A AU 2017206006A AU 2017206006 A AU2017206006 A AU 2017206006A AU 2017206006 B2 AU2017206006 B2 AU 2017206006B2
Authority
AU
Australia
Prior art keywords
culture
monoclonal antibody
species
fucose
feed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017206006A
Other languages
English (en)
Other versions
AU2017206006A1 (en
Inventor
Scott Gangloff
Kevin John JOSE
Sri MADABHUSHI
Marc Santoro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Outlook Therapeutics Inc
Original Assignee
Outlook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017206006(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Outlook Therapeutics Inc filed Critical Outlook Therapeutics Inc
Publication of AU2017206006A1 publication Critical patent/AU2017206006A1/en
Assigned to OUTLOOK THERAPEUTICS, INC. reassignment OUTLOOK THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: ONCOBIOLOGICS, INC.
Application granted granted Critical
Publication of AU2017206006B2 publication Critical patent/AU2017206006B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2017206006A 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition Active AU2017206006B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275384P 2016-01-06 2016-01-06
US62/275,384 2016-01-06
PCT/US2017/012349 WO2017120347A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Publications (2)

Publication Number Publication Date
AU2017206006A1 AU2017206006A1 (en) 2018-07-19
AU2017206006B2 true AU2017206006B2 (en) 2019-08-29

Family

ID=57944513

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017206006A Active AU2017206006B2 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Country Status (8)

Country Link
US (1) US20190161543A1 (enExample)
EP (1) EP3400241B1 (enExample)
JP (1) JP6674028B2 (enExample)
CN (1) CN109153716A (enExample)
AU (1) AU2017206006B2 (enExample)
CA (1) CA3010598A1 (enExample)
MX (1) MX2018008447A (enExample)
WO (1) WO2017120347A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
SG11202009216YA (en) * 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
JP2022514299A (ja) * 2018-12-19 2022-02-10 シージェン インコーポレイテッド 抗体の制御されたフコシル化
WO2021066772A1 (en) * 2019-10-01 2021-04-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Cell culture medium for reducing fucosylation and basic variants in the production of antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
WO2014055370A1 (en) * 2012-10-01 2014-04-10 Abbvie Biotherapeutics Inc. Compostions and methods for producing glycoproteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
JP5442251B2 (ja) 2005-05-26 2014-03-12 サイトス バイオテクノロジー アーゲー 拡張可能な発酵方法
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN102076865B (zh) * 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
PL2438171T3 (pl) * 2009-06-02 2015-04-30 Regeneron Pharma Komórki z niedoborem fukozylacji
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
MX2018004831A (es) * 2015-11-02 2018-08-01 Genentech Inc Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
WO2014055370A1 (en) * 2012-10-01 2014-04-10 Abbvie Biotherapeutics Inc. Compostions and methods for producing glycoproteins

Also Published As

Publication number Publication date
MX2018008447A (es) 2019-05-30
JP6674028B2 (ja) 2020-04-01
AU2017206006A1 (en) 2018-07-19
CN109153716A (zh) 2019-01-04
WO2017120347A1 (en) 2017-07-13
CA3010598A1 (en) 2017-07-13
JP2019500876A (ja) 2019-01-17
EP3400241A1 (en) 2018-11-14
US20190161543A1 (en) 2019-05-30
EP3400241B1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
AU2017206006B2 (en) Modulation of afucosylated species in a monoclonal antibody composition
CN105567627B (zh) 使用含高浓度氨基酸的培养基的细胞培养方法
US20190048070A1 (en) Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
RU2018119112A (ru) Композиции и способы на основе dac hyp
JP2012244993A5 (enExample)
US20230323420A1 (en) Perfusion medium
JP2019514383A (ja) 細胞培養培地
CN111465686B (zh) 动物细胞、动物细胞的制造方法及靶蛋白的制造方法
WO2020229584A1 (en) Method for reducing methionine oxidation in recombinant proteins
CN105820248A (zh) 一种新型抗egfr单克隆抗体的制备方法及应用
EP3374514A1 (en) Methods for modulating production profiles of recombinant proteins
JP2022529502A (ja) 抗ｃｄ３８抗体および製剤
RU2758674C2 (ru) Способы культивирования клеток
CN107460221B (zh) 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
US20130210075A1 (en) Enhanced protein expression
WO2017008736A1 (zh) 抗体依赖性细胞介导的细胞毒性增强的奥法木抗体
KR102190790B1 (ko) 변형된 egf 단백질의 생산 방법
Kuyucu et al. Cell line development and bioreactor process optimization for an atezolizumab biosimilar
WO2022219059A1 (en) Cell culture processes
HK1138038A (en) Cell culture method using amino acid-enriched medium

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: OUTLOOK THERAPEUTICS, INC.

Free format text: FORMER NAME(S): ONCOBIOLOGICS, INC.

FGA Letters patent sealed or granted (standard patent)